The BioFire Blood Culture Identification (BCID) panel is a rapid molecular test used to identify the causative agent of bloodstream infections (BSIs) in patients with positive blood cultures. It detects multiple pathogens and antimicrobial resistance genes in a single test, aiding in the timely management of sepsis and other BSI-related conditions. The panel is typically used on the BioFire FilmArray system.
Here’s a more detailed breakdown:
Purpose:
Rapid Identification:
The BCID panel helps quickly identify the specific bacteria, fungi, or other microorganisms responsible for a bloodstream infection.
Antimicrobial Resistance Detection:
It also detects genetic markers associated with antimicrobial resistance, allowing for better-targeted antibiotic therapy.
Improved Sepsis Management:
Rapid identification and resistance detection can lead to quicker adjustment of broad-spectrum antibiotics to more specific regimens, potentially reducing antibiotic use and hospital stay.
How it Works:
Multiplex PCR: The panel uses a multiplex PCR (polymerase chain reaction) technology to detect multiple targets simultaneously.
FilmArray System: It is designed for use with the BioFire FilmArray system.
Sample Preparation: A positive blood culture sample is processed, and the DNA is amplified and analyzed within the FilmArray system.
Benefits:
Faster Results:
The test provides results in about an hour from a positive blood culture, compared to days for traditional culture-based methods.

• Adenovirus
• Coronavirus 229E, HKU1, NL63, OC43
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
• Human metapneumovirus (HMPV)
• Human rhinovirus/enterovirus
• Influenza A (including subtypes H1, H3, and H1-2009)
• Influenza B
• Parainfluenza virus 1, 2, 3, and 4
• Respiratory syncytial virus (RSV) 

• Bordetella parapertussis
• Bordetella pertussis
• Chlamydia pneumoniae
• Mycoplasma pneumoniae